WO2015124727A1 - Fgf-18 compound dosing regimen - Google Patents

Fgf-18 compound dosing regimen Download PDF

Info

Publication number
WO2015124727A1
WO2015124727A1 PCT/EP2015/053624 EP2015053624W WO2015124727A1 WO 2015124727 A1 WO2015124727 A1 WO 2015124727A1 EP 2015053624 W EP2015053624 W EP 2015053624W WO 2015124727 A1 WO2015124727 A1 WO 2015124727A1
Authority
WO
WIPO (PCT)
Prior art keywords
fgf
compound
cartilage
use according
weeks
Prior art date
Application number
PCT/EP2015/053624
Other languages
English (en)
French (fr)
Inventor
Christoph H. Ladel
Hans Guehring
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to LTEP15706006.2T priority Critical patent/LT3107559T/lt
Priority to CA2938791A priority patent/CA2938791A1/en
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to KR1020167025245A priority patent/KR102410988B1/ko
Priority to US15/120,131 priority patent/US9889179B2/en
Priority to MX2016010871A priority patent/MX2016010871A/es
Priority to RU2016137289A priority patent/RU2691946C2/ru
Priority to JP2016553329A priority patent/JP6431083B2/ja
Priority to AU2015220773A priority patent/AU2015220773B2/en
Priority to CN201580020536.2A priority patent/CN106232622A/zh
Priority to SG11201606505UA priority patent/SG11201606505UA/en
Priority to EP15706006.2A priority patent/EP3107559B1/en
Priority to SI201530428T priority patent/SI3107559T1/sl
Priority to RS20181168A priority patent/RS57709B1/sr
Priority to NZ723148A priority patent/NZ723148A/en
Priority to BR112016018685A priority patent/BR112016018685A2/pt
Priority to PL15706006T priority patent/PL3107559T3/pl
Priority to DK15706006.2T priority patent/DK3107559T3/en
Priority to ES15706006.2T priority patent/ES2689071T3/es
Publication of WO2015124727A1 publication Critical patent/WO2015124727A1/en
Priority to IL247083A priority patent/IL247083B/en
Priority to ZA2016/05547A priority patent/ZA201605547B/en
Priority to HRP20181570TT priority patent/HRP20181570T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/EP2015/053624 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen WO2015124727A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
PL15706006T PL3107559T3 (pl) 2014-02-20 2015-02-20 Schemat dawkowania związku FGF-18
SG11201606505UA SG11201606505UA (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen
KR1020167025245A KR102410988B1 (ko) 2014-02-20 2015-02-20 Ｆｇｆ－１８ 화합물 투여 처방
US15/120,131 US9889179B2 (en) 2014-02-20 2015-02-20 FGF-18 compound dosing regimen
MX2016010871A MX2016010871A (es) 2014-02-20 2015-02-20 Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.
RU2016137289A RU2691946C2 (ru) 2014-02-20 2015-02-20 Схема применения соединения fgf-18
JP2016553329A JP6431083B2 (ja) 2014-02-20 2015-02-20 Ｆｇｆ−１８化合物の投与計画
AU2015220773A AU2015220773B2 (en) 2014-02-20 2015-02-20 FGF-18 compound dosing regimen
SI201530428T SI3107559T1 (sl) 2014-02-20 2015-02-20 Režim odmerjanja spojine FGF-18
LTEP15706006.2T LT3107559T (lt) 2014-02-20 2015-02-20 Fgf-18 junginio dozavimo režimas
EP15706006.2A EP3107559B1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen
CN201580020536.2A CN106232622A (zh) 2014-02-20 2015-02-20 Fgf‑18化合物给药方案
RS20181168A RS57709B1 (sr) 2014-02-20 2015-02-20 Dozni režim fgf-18 jedinjenja
NZ723148A NZ723148A (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen
BR112016018685A BR112016018685A2 (pt) 2014-02-20 2015-02-20 regime de dosagem com composto de fgf-18
CA2938791A CA2938791A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen
DK15706006.2T DK3107559T3 (en) 2014-02-20 2015-02-20 Dosage schedule for FGF-18 compound
ES15706006.2T ES2689071T3 (es) 2014-02-20 2015-02-20 Régimen de dosificación del compuesto FGF-18
IL247083A IL247083B (en) 2014-02-20 2016-08-03 dose fgh–18
ZA2016/05547A ZA201605547B (en) 2014-02-20 2016-08-10 Fgf-18 compound dosing regimen
HRP20181570TT HRP20181570T1 (hr) 2014-02-20 2018-10-02 Režim doziranja spoja fgf-18

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14000600.8 2014-02-20
EP14000600 2014-02-20

Publications (1)

Publication Number Publication Date
WO2015124727A1 true WO2015124727A1 (en) 2015-08-27

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen
PCT/EP2015/053624 WO2015124727A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Country Status (25)

Country Link
US (2) US9889179B2 (ja)
EP (2) EP3119417B1 (ja)
JP (2) JP6431083B2 (ja)
KR (2) KR102410988B1 (ja)
CN (2) CN106456713A (ja)
AR (2) AR099558A1 (ja)
AU (2) AU2015220773B2 (ja)
BR (2) BR112016018696A2 (ja)
CA (2) CA2938793A1 (ja)
DK (2) DK3107559T3 (ja)
ES (2) ES2688551T3 (ja)
HR (2) HRP20181572T1 (ja)
HU (1) HUE040350T2 (ja)
IL (2) IL247084B (ja)
LT (2) LT3107559T (ja)
MX (2) MX2016010872A (ja)
NZ (2) NZ723148A (ja)
PL (2) PL3119417T3 (ja)
PT (2) PT3119417T (ja)
RS (2) RS57709B1 (ja)
RU (2) RU2691946C2 (ja)
SG (2) SG11201606505UA (ja)
SI (2) SI3119417T1 (ja)
WO (2) WO2015124731A1 (ja)
ZA (2) ZA201605548B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724388B2 (en) 2014-02-20 2017-08-08 Merck Patent Gmbh FGF-18 compound dosing regimen
US10086112B2 (en) 2014-02-20 2018-10-02 Merck Patent Gmbh Implant comprising FGF-18
WO2020161341A1 (en) * 2019-02-08 2020-08-13 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis
US11344540B2 (en) 2016-02-22 2022-05-31 Novartis Ag Methods for treating liver disorders using FXR agonists

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111164429A (zh) * 2017-09-29 2020-05-15 默克专利有限公司 预测对fgf-18化合物反应性的炎性生物标志物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023063A2 (en) * 2006-08-25 2008-02-28 Ares Trading S.A. Treatment of cartilage disorders with fgf-18

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
EP1896053B1 (en) * 2004-07-06 2018-10-31 ZymoGenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
EP1978997A1 (en) * 2005-12-22 2008-10-15 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
ES2392883T3 (es) * 2006-08-25 2012-12-14 Ares Trading S.A. Tratamiento de trastornos de cartílagos con FGF-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
EP2688890B1 (en) * 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
AU2015220781B2 (en) 2014-02-20 2018-05-24 Merck Patent Gmbh FGF-18 in graft transplantation and tissue engineering procedures
WO2015124739A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Implant comprising fgf-18
SG11201606505UA (en) 2014-02-20 2016-09-29 Merck Patent Gmbh Fgf-18 compound dosing regimen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023063A2 (en) * 2006-08-25 2008-02-28 Ares Trading S.A. Treatment of cartilage disorders with fgf-18

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ELLSWORTH J L ET AL: "Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 10, no. 4, 1 April 2002 (2002-04-01), pages 308 - 320, XP002374609, ISSN: 1063-4584, DOI: 10.1053/JOCA.2002.0514 *
LOHMANDER L STEFAN ET AL: "Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.", July 2014, ARTHRITIS & RHEUMATOLOGY (HOBOKEN, N.J.) JUL 2014, VOL. 66, NR. 7, PAGE(S) 1820 - 1831, ISSN: 2326-5205, XP002734752 *
POWER JONATHON ET AL: "Intra-articular injection of rhFGF-18 improves the healing in microfracture treated chondral defects in an ovine model.", 16 January 2014, JOURNAL OF ORTHOPAEDIC RESEARCH : OFFICIAL PUBLICATION OF THE ORTHOPAEDIC RESEARCH SOCIETY MAY 2014, VOL. 32, NR. 5, PAGE(S) 669 - 676, ISSN: 1554-527X, XP002734751 *
SHIMOAKA TAKASHI ET AL: "Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10", THE JOURNAL OF BIOLOGICAL CHEMISTRY 1 MAR 2002,, vol. 277, no. 9, 1 March 2002 (2002-03-01), pages 7493 - 7500, XP002527434, DOI: 10.1074/JBC.M108653200 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724388B2 (en) 2014-02-20 2017-08-08 Merck Patent Gmbh FGF-18 compound dosing regimen
US10086112B2 (en) 2014-02-20 2018-10-02 Merck Patent Gmbh Implant comprising FGF-18
US11344540B2 (en) 2016-02-22 2022-05-31 Novartis Ag Methods for treating liver disorders using FXR agonists
WO2020161341A1 (en) * 2019-02-08 2020-08-13 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis

Also Published As

Publication number Publication date
RU2700582C2 (ru) 2019-09-18
PL3119417T3 (pl) 2019-01-31
ES2688551T3 (es) 2018-11-05
HRP20181570T1 (hr) 2018-11-30
LT3107559T (lt) 2018-10-25
ES2689071T3 (es) 2018-11-08
CN106456713A (zh) 2017-02-22
IL247083A0 (en) 2016-09-29
JP2017512194A (ja) 2017-05-18
WO2015124731A1 (en) 2015-08-27
MX2016010872A (es) 2016-11-17
RS57853B1 (sr) 2018-12-31
AR099510A1 (es) 2016-07-27
RU2016137289A3 (ja) 2018-10-19
EP3107559A1 (en) 2016-12-28
JP2017507142A (ja) 2017-03-16
US20170072017A1 (en) 2017-03-16
RU2016137292A3 (ja) 2018-09-17
AU2015220777B2 (en) 2020-10-22
JP6431082B2 (ja) 2018-11-28
EP3119417A1 (en) 2017-01-25
SI3119417T1 (sl) 2018-11-30
LT3119417T (lt) 2018-10-25
CA2938793A1 (en) 2015-08-27
RU2691946C2 (ru) 2019-06-19
AU2015220773A1 (en) 2016-09-01
RU2016137292A (ru) 2018-03-21
EP3119417B1 (en) 2018-07-11
ZA201605548B (en) 2018-12-19
KR20160116001A (ko) 2016-10-06
AU2015220777A1 (en) 2016-09-01
CA2938791A1 (en) 2015-08-27
SG11201606505UA (en) 2016-09-29
IL247084A0 (en) 2016-09-29
IL247083B (en) 2019-09-26
BR112016018696A2 (pt) 2017-10-17
EP3107559B1 (en) 2018-07-11
BR112016018685A2 (pt) 2017-10-17
ZA201605547B (en) 2019-09-25
US9889179B2 (en) 2018-02-13
HRP20181572T1 (hr) 2018-11-30
JP6431083B2 (ja) 2018-11-28
RS57709B1 (sr) 2018-12-31
SI3107559T1 (sl) 2018-11-30
PT3119417T (pt) 2018-10-31
DK3107559T3 (en) 2018-10-15
US9724388B2 (en) 2017-08-08
AR099558A1 (es) 2016-08-03
NZ723148A (en) 2022-08-26
IL247084B (en) 2019-09-26
MX2016010871A (es) 2016-11-17
US20170056474A1 (en) 2017-03-02
KR20160116000A (ko) 2016-10-06
KR102410988B1 (ko) 2022-06-17
NZ723139A (en) 2022-12-23
AU2015220773B2 (en) 2020-10-08
PL3107559T3 (pl) 2019-01-31
SG11201606502YA (en) 2016-09-29
DK3119417T3 (en) 2018-10-22
KR102410986B1 (ko) 2022-06-17
CN106232622A (zh) 2016-12-14
PT3107559T (pt) 2018-10-31
RU2016137289A (ru) 2018-03-21
HUE040350T2 (hu) 2019-03-28

Similar Documents

Publication Publication Date Title
KR101419961B1 (ko) Ｆｇｆ-18 로 연골 질환의 치료
AU2015220773B2 (en) FGF-18 compound dosing regimen
NZ574216A (en) Treatment of cartilage disorders with fgf-18
JP2023058550A (ja) 変形性関節症の治療に使用するための製剤
RU2745453C2 (ru) Комбинированная композиция, содержащая соединение fgf-18

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15706006

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 247083

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2938791

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016553329

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15120131

Country of ref document: US

Ref document number: MX/A/2016/010871

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016018685

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2015220773

Country of ref document: AU

Date of ref document: 20150220

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167025245

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015706006

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015706006

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016137289

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016018685

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160815